Codexis, Inc. - Common Stock (CDXS)

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

CDXS stock results show that Codexis missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). 

Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.

Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market trading. Here are some other stocks moving in pre-market trading.

Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.

While trying to find the next Nvidia is a wildly risky proposition, these AI stocks to buy could be your ticket to extraordinary gains.

Codexis Inc (NASDAQ: CDXS) intends to prioritize advancing and commercializing its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform and its